|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1640 RHODE ISLAND AVENUE, NW |
Address2 | SUITE 600 |
City | WASHINGTON |
State | DC |
Zip Code | 20036 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 61458-1406
|
||||||||
|
6. House ID# 353940050
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Robert Raben, President |
Date | 10/22/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.
Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R.4395, the Cosmetic Safety Amendments Act of 2012
The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics.
H.R. 4262, the Cosmetics Safety Enhancement Act of 2012
The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
S. 3237, the Accelerating the End of Breast Cancer Act of 2012.
The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, opposing appropriations riders limiting the work of the National Toxicology Program's Report on Carcinogens, and increasing support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Consumer Product Safety Commission (CPSC), Natl Institutes of Health (NIH), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robert |
Raben |
|
|
|
Katherine |
Huffman |
|
|
|
Randi |
Moore |
|
|
|
Daniel |
Penchina |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |